Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options
- PMID: 24669181
- PMCID: PMC3956387
Item in Clipboard
Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options
P T.
2014 Feb.
Abstract
A survival benefit has been demonstrated or is under investigation as the primary outcome among certain recently approved agents and investigational agents for men with metastatic castration-resistant prostate cancer that has spread to bone.
Figures
Probability of invasive prostate cancer development, by age group. Source: American Cancer Society, 2013.
Similar articles
-
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Eur Urol. 2019. PMID: 29673712 Review.
-
New and emerging agents for the treatment of castration-resistant prostate cancer.Urol Oncol. 2011 Nov-Dec;29(6 Suppl):S1-8. doi: 10.1016/j.urolonc.2011.08.013. Urol Oncol. 2011. PMID: 22074657 Review.
-
Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.Cancer. 2016 Jan 15;122(2):222-9. doi: 10.1002/cncr.29748. Epub 2015 Oct 20. Cancer. 2016. PMID: 26484853
-
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. J Urol. 2015. PMID: 26196735 Review.
-
Bone Imaging in Metastatic Castration-resistant Prostate Cancer; Where do we Stand.Curr Radiopharm. 2017 Nov 10;10(3):171-177. doi: 10.2174/1874471010666170816125907. Curr Radiopharm. 2017. PMID: 28814252 Review.
Cited by
-
Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.Cancer Lett. 2022 Jan 28;525:170-178. doi: 10.1016/j.canlet.2021.10.042. Epub 2021 Nov 6. Cancer Lett. 2022. PMID: 34752846 Free PMC article.
-
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.Eur Urol Oncol. 2018 Dec;1(6):449-458. doi: 10.1016/j.euo.2018.06.004. Epub 2018 Sep 14. Eur Urol Oncol. 2018. PMID: 31158087 Free PMC article. Clinical Trial.
-
Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.Front Oncol. 2018 May 24;8:180. doi: 10.3389/fonc.2018.00180. eCollection 2018. Front Oncol. 2018. PMID: 29911070 Free PMC article. Review.
-
The gut microbiota can be a potential regulator and treatment target of bone metastasis.Biochem Pharmacol. 2022 Mar;197:114916. doi: 10.1016/j.bcp.2022.114916. Epub 2022 Jan 15. Biochem Pharmacol. 2022. PMID: 35041811 Free PMC article. Review.
-
Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.Molecules. 2021 Apr 9;26(8):2162. doi: 10.3390/molecules26082162. Molecules. 2021. PMID: 33918705 Free PMC article. Review.
References
-
- American Cancer Society (ACS) Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.
-
- Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. - PubMed
-
- Scher HI, Fizazi K, Saad F, et al. the AFFIRM Investigators Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. - PubMed
-
- Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1998–1999;17(4):331–336. - PubMed
LinkOut - more resources
Full Text Sources